Ö. Türeci

626 total citations · 1 hit paper
5 papers, 440 citations indexed

About

Ö. Türeci is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Neurology. According to data from OpenAlex, Ö. Türeci has authored 5 papers receiving a total of 440 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Pulmonary and Respiratory Medicine, 4 papers in Oncology and 3 papers in Neurology. Recurrent topics in Ö. Türeci's work include Gastric Cancer Management and Outcomes (5 papers), Barrier Structure and Function Studies (3 papers) and Pancreatic and Hepatic Oncology Research (3 papers). Ö. Türeci is often cited by papers focused on Gastric Cancer Management and Outcomes (5 papers), Barrier Structure and Function Studies (3 papers) and Pancreatic and Hepatic Oncology Research (3 papers). Ö. Türeci collaborates with scholars based in Germany, Ukraine and Russia. Ö. Türeci's co-authors include Martin Schüler, Florian Lordick, Christoph Huber, Uğur Şahin, J.W. Park, Kai Wiechen, Karl Dhaene, Daniel Maurus, Ahsan M. Arozullah and I. Bazin and has published in prestigious journals such as Annals of Oncology.

In The Last Decade

Ö. Türeci

5 papers receiving 435 citations

Hit Papers

FAST: a randomised phase II study of zolbetuximab (IMAB36... 2021 2026 2022 2024 2021 50 100 150 200
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma
    2021 244 citations Uğur Şahin, Ö. Türeci et al. Annals of Oncology profile →

Peers

Ö. Türeci
Comparison fields: 5 of 37
  • Pulmonary and Respiratory Medicine 260
  • Oncology 211
  • Neurology 156
  • Surgery 135
  • Gastroenterology 70
Replace J.W. Park with:
J.W. Park United States
Özlem Türeci Germany
Rachel Popow United States
Benjamin L. Green United States
Megan H. Crawley United States
Michihiko Kogure Japan
Osamu Shinto Japan
Claudia Gedlicka Austria
J.W. Park United States View profile →
Citations per field, relative to Ö. Türeci
Ö. Türeci · 1×
Citations per year, relative to Ö. Türeci
Ö. Türeci · 1×

Countries citing papers authored by Ö. Türeci

Since Specialization
Citations

This map shows the geographic impact of Ö. Türeci's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ö. Türeci with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ö. Türeci more than expected).

Fields of papers citing papers by Ö. Türeci

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ö. Türeci. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ö. Türeci. The network helps show where Ö. Türeci may publish in the future.

Co-authorship network of co-authors of Ö. Türeci

This figure shows the co-authorship network connecting the top 25 collaborators of Ö. Türeci. A scholar is included among the top collaborators of Ö. Türeci based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ö. Türeci. Ö. Türeci is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

5 of 5 papers shown
# Work Indexed citations
1
FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma breakdown →
2021 ·Annals of Oncology ·Uğur Şahin, Ö. Türeci, Georgy M. Manikhas, Florian Lordick, Andriy Rusyn, Ihor Vynnychenko, Assen Dudov, I. Bazin, Igor Bondarenko, Bohuslav Melichar, Karl Dhaene, Kai Wiechen, Christoph Huber, Daniel Maurus, Ahsan M. Arozullah, J.W. Park, Martin Schüler, S. Al-Batran
244
2
A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study
2019 ·Annals of Oncology ·Ö. Türeci, Uğur Şahin, Henning Schulze‐Bergkamen, Zanete Zvirbule, Florian Lordick, Dieter Koeberle, Peter Thuss‐Patience, Thomas J. Ettrich, Dirk Arnold, Florian Bassermann, S-E. Al-Batran, Kai Wiechen, Karl Dhaene, Daniel Maurus, Michael A. Gold, Christoph Huber, Andrew Krivoshik, Ahsan M. Arozullah, J.W. Park, Martin Schüler
161
3
Final results of the FAST study, an international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without the anti-CLDN18.2 antibody IMAB362 as first-line therapy in patients with advanced CLDN18.2+ gastric and gastroesophageal junction (GEJ) adenocarcinoma
2016 ·Annals of Oncology ·Martin Schüler, S-E. Al-Batran, Zanete Zvirbule, George Manikhas, Florian Lordick, Andriy Rusyn, Yuriy Vinnyk, Ihor Vynnychenko, Natalia Fadeeva, M. Nechaeva, Assen Dudov, (unknown), (unknown), I. Bazin, Igor Bondarenko, Bohuslav Melichar, Christoph Huber, Ö. Türeci, Uğur Şahin
18
4
220O Claudin 18.2 – a novel treatment target in the multicenter, randomized, phase II FAST study, a trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without the anti-CLDN18.2 antibody IMAB362 as 1st line therapy in advanced gastric and gastroesophageal junction (GEJ) cancer
2016 ·Annals of Oncology ·(unknown), (unknown), S-E. Al-Batran, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Uğur Şahin, Ö. Türeci
3
5
Efficacy and Safety of Multiple Doses of Imab362 in Patients with Advanced Gastro-Esophageal Cancer: Results of a Phase Ii Study
2014 ·Annals of Oncology ·Tanja Trarbach, Martin Schüler, Zanete Zvirbule, Florian Lordick, (unknown), (unknown), Henning Schulze‐Bergkamen, Peter Thuss‐Patience, (unknown), Wolff Schmiegel, Sebastian Bauer, Carolyn Muller, S-E. Al-Batran, Christoph Huber, Daniel Maurus, (unknown), Uğur Şahin, Ö. Türeci
14

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by J.W. Park Breakdown of academic impact, for papers by Özlem Türeci Breakdown of academic impact, for papers by Rachel Popow Breakdown of academic impact, for papers by Benjamin L. Green Breakdown of academic impact, for papers by Megan H. Crawley Breakdown of academic impact, for papers by Michihiko Kogure Breakdown of academic impact, for papers by Osamu Shinto Breakdown of academic impact, for papers by Claudia Gedlicka
Rankless by CCL
2026